
THORATEC CORP Form 10-Q November 07, 2011 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



COMMISSION FILE NUMBER: 000-49798

THORATEC CORPORATION

(Exact name of registrant as specified in its charter)

California

(State or other jurisdiction of incorporation or organization)

94-2340464

(I.R.S. Employer Identification No.)

6035 Stoneridge Drive, Pleasanton, California

(Address of principal executive offices)

94588

(Zip Code)

(925) 847-8600

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x

Accelerated filer o

Non-accelerated filer o (Do not check if smaller reporting company)

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes o No x

As of October 21, 2011, the registrant had 59,927,911 shares of common stock outstanding.

Table of Contents

THORATEC CORPORATION

TABLE OF CONTENTS

Part I. Financial Information	3
Item 1. Unaudited Condensed Consolidated Financial Statements	3
Condensed Consolidated Balance Sheets as of October 1, 2011 and January 1, 2011	
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended October 1, 2011 and October 2, 2010	4
Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended October 1, 2011 and October 2,	
<u>2010</u>	4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended October 1, 2011 and October 2, 2010	5
Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3. Quantitative and Qualitative Disclosure of Market Risk	33
<u>Item 4. Controls and Procedures</u>	34
Part II. Other Information	35
Item 1. Legal Proceedings	35
<u>Item 1A. Risk Factors</u>	35
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	35
<u>Item 6. Exhibits</u>	36
<u>Signatures</u>	37
Exhibits	
<u>EX-10.51</u>	
<u>EX-31.1</u>	
EX-31.2	
<u>EX-32.1</u>	
EX-32.2	
EX-101 INSTANCE DOCUMENT	
EX-101 SCHEMA DOCUMENT	
EX-101 CALCULATION LINKBASE DOCUMENT	
EX-101 LABELS LINKBASE DOCUMENT	
EX-101 PRESENTATION LINKBASE DOCUMENT	

Thoratec, the Thoratec logo, Thoralon, HeartMate, HeartMate II, and GoGear are registered trademarks of Thoratec Corporation, and IVAD is a trademark of Thoratec Corporation.

 $CentriMag\ and\ PediMag\ are\ registered\ trademarks\ of\ Thoratec\ LLC\ and\ PediVAS\ is\ a\ registered\ trademark\ of\ Levitronix\ Switzerland\ GmbH.$

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THORATEC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands)

	O	ctober 1, 2011	January 1, 2011
ASSETS			
Current assets:			
Cash and cash equivalents	\$	62,775	\$ 56,887
Short-term available-for-sale investments		153,896	391,256
Receivables, net of allowances of \$1,884 and \$1,334, respectively		55,234	57,213
Inventories		63,107	59,790
Deferred tax assets		9,651	9,677
Income tax receivable		4,884	9,538
Prepaid expenses and other assets		5,520	5,706
Total current assets		355,067	590,067
Property, plant and equipment, net		39,554	38,077
Goodwill		195,293	95,015
Purchased intangible assets, net		95,150	88,518
Long-term available-for-sale investments		15,935	21,379
Other long-term assets		6,145	4,687
Total Assets	\$	707,144	\$ 837,743
LIABILITIES AND SHAREHOLDERS EQUITY			
Current liabilities:			
Accounts payable	\$	13,817	\$ 13,495
Accrued compensation		17,711	20,753
Other accrued liabilities		13,640	14,604
Senior subordinated convertible notes			138,165
Total current liabilities		45,168	187,017
Long-term deferred tax liability		20,295	20,109
Other long-term liabilities		8,555	9,257
Contingent liabilities		22,990	
Total Liabilities		97,008	216,383
Shareholders equity:			
Common shares: no par, authorized 100,000; issued and outstanding 59,923 and 58,571 as of			
October 1, 2011 and January 1, 2011, respectively			
Additional paid-in capital		589,816	606,782
Retained earnings		40,242	18,603

Accumulated other comprehensive loss:

Unrealized loss on investments	(1,674)	(1,660)
Cumulative translation adjustments	(18,248)	(2,365)
Total accumulated other comprehensive loss	(19,922)	(4,025)
Total Shareholders Equity	610,136	621,360
Total Liabilities and Shareholders Equity	\$ 707,144 \$	837,743

See notes to the unaudited condensed consolidated financial statements.

Table of Contents

THORATEC CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share data)

	Three Months Ended		Nine Mont	ed		
	October 1,		October 2,	October 1,		October 2,
	2011		2010	2011		2010
Product sales	\$ 102,584	\$	90,996	\$ 313,335	\$	285,366
Cost of product sales	30,898		28,621	93,043		90,771
Gross profit	71,686		62,375	220,292		194,595
Operating expenses:						
Selling, general and administrative	25,062		21,104	76,275		64,010
Research and development	16,273		12,332	47,826		44,135
Amortization of purchased intangible assets	2,609		2,446	7,108		7,326
Total operating expenses	43,944		35,882	131,209		115,471
Income from operations	27,742		26,493	89,083		79,124
Other income and (expense):						
Interest expense and other	(3)		(3,125)	(4,650)		(9,280)
Interest income and other	283		1,362	1,526		4,261
Impairment on investment			(11)			(2,057)
Income before income taxes	28,022		24,719	85,959		72,048
Income tax expense	(9,033)		(9,239)	(28,729)		(25,667)
Income from continuing operations	18,989		15,480	57,230		46,381
Loss from discontinued operations (net of tax)	(1,031)		(1,183)	(1,031)		(3,697)
Net income	\$ 17,958	\$	14,297	\$ 56,199	\$	42,684
Income (loss) per share Basic:						
Continuing operations	\$ 0.32	\$	0.26	\$ 0.97	\$	0.80
Discontinued operations	(0.02)		(0.02)	(0.02)		(0.06)
Net income	\$ 0.30	\$	0.24	\$ 0.95	\$	0.74
Income (loss) per share Diluted:						
Continuing operations	\$ 0.31	\$	0.26	\$ 0.95	\$	0.78
Discontinued operations	(0.02)		(0.02)	(0.02)		(0.06)
Net income	\$ 0.29	\$	0.24	\$ 0.93	\$	0.72
Shares used to compute income (loss) per						
share:						
Basic	59,763		58,138	58,630		57,473
Diluted	60,666		66,612	63,306		66,216

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Three Months Ended October 1, 2011 October 2, 2010

Nine Months Ended October 1, 2011

October 2, 2010

(in thousands)

Net income	\$ 17,958	\$ 14,297	\$ 56,199	\$ 42,684
Unrealized gains (losses) on investments (net				
of taxes of \$128 and \$92 for the three months				
ended October 1, 2011 and October 2, 2010,				
respectively, and \$9 and \$252 for the nine				
months ended October 1, 2011 and October 2,				
2010, respectively)	(209)	116	(14)	(591)
Foreign currency translation adjustments	(17,073)	1,157	(15,883)	(589)
Total other comprehensive (loss) income	(17,282)	1,273	(15,897)	(1,180)
Comprehensive income	\$ 676	\$ 15,570	\$ 40,302	\$ 41,504

See notes to the unaudited condensed consolidated financial statements.

Table of Contents

THORATEC CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

	(Nine Mont October 1, 2011	Ended October 2, 2010		
Cash flows from continuing operating activities:					
Income from continuing operations	\$	57,230	\$ 46,381		
Adjustments to reconcile net income from continuing operations to net cash					
provided by operating activities:					
Depreciation and amortization		12,818	12,309		
Investment premium amortization, net		2,935	3,795		
Loss on extinguishment of senior subordinated convertible notes			99		
Non-cash interest income and other		378	687		
Non-cash interest expense		2,815	7,152		
Write-down on investment			2,057		
Tax benefit related to stock options		1,348	10,343		
Share-based compensation expense		11,732	9,624		
Excess tax benefits from share-based compensation		(1,397)	(9,458)		
Loss on disposal of assets		26	529		
Change in deferred taxes, net		(4,055)	(4,027)		
Changes in assets and liabilities, net of acquisition of Levitronix Medical:					
Receivables		4,268	(3,080)		
Inventories		779	(15,939)		
Prepaid expenses and other assets		(271)	(277)		
Accrued compensation and other accrued liabilities		(4,490)	10,310		
Accounts payable		(1,021)	4,718		
Income taxes, net		4,018	(13,851)		
Net cash provided by continuing operating activities		87,113	61,372		
Cash flows from continuing investing activities:					
Purchases of available-for-sale investments		(236,399)	(398,874)		
Sales and maturities of available-for-sale investments		476,264	338,613		
Acquisition of Levitronix Medical, net of cash acquired		(109,974)			
Loan collections			2,756		